Technology evaluation: cintredekin besudotox, NeoPharm/Nippon.
NeoPharm Inc, under license from the National Institutes of Health and the FDA, and in collaboration with the Japanese licensee Nippon Kayaku Co Ltd, is developing cintredekin besudotox, a chimeric human IL-13 conjugated to a genetically engineered Pseudomonas exotoxin molecule, as a potential antitumor agent. This agent is currently undergoing phase III clinical trials.
Rainov
Nikolai G
NG
University of Liverpool, Department of Neurological Science, The Walton Centre for Neurology and Neurosurgery NHS Trust, Lower Lane, Liverpool L9 7LJ, UK. N.G.Rainov@liverpool.ac.uk
Söling
Ariane
A
D000818:Animals; D002986:Clinical Trials as Topic; D005098:Exotoxins / Q000235:genetics / Q000494:pharmacology* / Q000633:toxicity; D005910:Glioma / Q000188:drug therapy*; D006801:Humans; D018793:Interleukin-13 / Q000235:genetics / Q000494:pharmacology* / Q000633:toxicity; D051379:Mice; D011993:Recombinant Fusion Proteins / Q000235:genetics / Q000494:pharmacology* / Q000633:toxicity; D015173:Supratentorial Neoplasms / Q000188:drug therapy*
D005098:Exotoxins; D018793:Interleukin-13; D011993:Recombinant Fusion Proteins